![](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/07\/syringe-pill-capsule-morphine-needle-liquid-medicine-medical-treatment-medicament-cure-injection-ill.jpeg\")
Photo by qimono on Pixabay
\nThe Discount Patience Buys You<\/b><\/p>\n
The real story here is the forward valuation discount. While you pay about 23.1 times this year\u2019s earnings, that same $425.6 share price is only about 17.0 times the earnings analysts expect by 2028. As the company\u2019s profits grow into the current stock price, the multiple you paid effectively shrinks on its own. That\u2019s a 26% lower multiple three years from now, a discount that accrues to a patient holder.<\/p>\n
Is the Growth Behind the Discount Believable?<\/b><\/p>\n
A discount is only as good as the growth that creates it. The honest question is whether the consensus earnings growth of about 16.5% a year is credible. Let\u2019s test it. First, analysts expect revenue to grow about 4.3% a year. That\u2019s actually well below the 9.7% revenue growth the company delivered over the last twelve months, suggesting the forecast is cautious. If recent momentum holds, the discount could be understated.<\/p>\n
Second, we can check Wall Street\u2019s numbers against the company\u2019s own. Management\u2019s guidance for 2026 adjusted earnings is \u201cabout 18.2\u201d per share. The analyst consensus for the year is $18.39. They are forecasting almost exactly in line with what management itself projects, which lends the growth path more weight. On the latest earnings call, management pointed to concrete drivers, noting that at UnitedHealthcare, \u201cpricing is improving relative to elevated health care cost trends,\u201d while at Optum Health, \u201coperational improvements continue to take hold.\u201d<\/p>\n
The Risk In A Premium Name<\/b><\/p>\n
Of course, no growth is guaranteed. A stock priced for future earnings can be unforgiving when sentiment shifts. In past market shocks, UnitedHealth stock has fallen as much as 72% from peak to trough. The forward discount rewards patience, but it doesn\u2019t eliminate market risk.<\/p>\n
How An Investor Gets Paid<\/b><\/p>\n
It\u2019s crucial to understand how this pays off. If the stock price never moves, by 2028 you\u2019d simply own a company trading at about 17.0 times earnings. This proves you didn\u2019t overpay; it\u2019s your margin of safety. The actual reward comes from price appreciation, which happens only if the market continues to value those growing earnings at a healthy multiple.<\/p>\n
Consider a scenario where the multiple settles at about 20.1 times by 2028, halfway between today\u2019s level and that 17.0 times floor. That would put the stock about 18% higher than today. If the market keeps paying a multiple closer to today\u2019s 23.1 times, the gain would be larger. The story of another healthcare major, CVS Health, also shows how a focus on future earnings<\/a> can reframe a stock\u2019s value.<\/p>\n The Price You\u2019re Really Paying<\/b><\/p>\n The premium you see on UnitedHealth today is not the full story. On the earnings analysts expect just a few years out, today\u2019s price implies a much more ordinary multiple. Even if the stock stalls, a patient holder is not overpaying for the growth that\u2019s priced in. If the market keeps rewarding that growth as it arrives, the stock price compounds with it. To see if the story is on track, watch the company\u2019s medical care ratio. Its improvement in the first quarter was a key sign of progress, and its stability would confirm that management\u2019s operational fixes are delivering sustainable earnings.<\/p>\n And UnitedHealth is far from alone. Our Forward Valuation Discount rankings<\/a> sort the entire S&P 500 by how little you are really paying for each name\u2019s growth once the out-year earnings land. See where you are overpaying least, and where the growth behind the discount looks most believable.<\/p>\n And if it is exposure to managed health care as a whole you want rather than this one name, a managed health care ETF like IHF<\/a> covers that single sector.<\/p>\n Cheap Or Rich, Concentration Is The Real Risk<\/b><\/p>\n Valuation tells you what one stock might be worth \u2013 it says nothing about how much of your wealth should sit in it. When a single name dominates your portfolio, a re-rating the wrong way is not a paper loss, it is years of savings, and unwinding it later means a tax bill. There is a way to cap the downside and unwind it tax-efficiently<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"The healthcare giant looks expensive at a glance, but a patient investor is effectively buying its future earnings…\n","protected":false},"author":3,"featured_media":923674,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[35],"tags":[84538,267074,66685,48592,372781,372778,210,1141,1142,372780,372782,104264,372777,67,132,68,372779],"class_list":["post-923673","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-analyst-estimates","tag-ci","tag-cnc","tag-cvs","tag-elv","tag-forward-valuation","tag-health","tag-health-care","tag-healthcare","tag-hnw-investing","tag-hum","tag-portfolio-risk","tag-unh","tag-united-states","tag-unitedstates","tag-us","tag-valuation-discount"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116891303223997857","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/923673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=923673"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/923673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/923674"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=923673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=923673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=923673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}